Gemcitabine/nab-paclitaxel (G/A) alternating with 5-FU/leucovorin/irinotecan (FOLFIRI) in 1st line metastatic pancreatic cancer (MPC).

Vincent J. Picozzi,Bruce S. Lin,Margaret T. Mandelson

Gemcitabine/nab-paclitaxel (G/A) alternating with 5-FU/leucovorin/irinotecan (FOLFIRI) in 1st line metastatic pancreatic cancer (MPC).

2018

Vincent J. Picozzi
Bruce S. Lin
Margaret T. Mandelson

e16218Background: The use of alternating chemotherapy regimens in cancer therapy may 1)lessen toxicity 2) slow emergence of resistant cancer biology thus improving outcomes and 3) provide a broader...

Keywords:

FOLFIRI
Metastatic pancreatic cancer
Nab-paclitaxel
Cancer research
Pathology
Gemcitabine
Irinotecan
Medicine
Toxicity
alternating chemotherapy
Oncology
Internal medicine
cancer therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations